Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed disability progression in people with nrSPMS, a population for which there are currently no approved therapies a...
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.
French drugmaker Sanofi will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said on Thursday.
Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning potential, making it reliant on revenue streams from Sanofi. Novavax's long-term prospects may be challenging as it may struggle to develop new products and could see its revenue streams dry up post-2025.
Sanofi (NASDAQ:SNY ) Q2 2024 Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Thomas Kudsk - Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Brian Foard - Executive Vice President & Head-Specialty Care, Sanofi Tho...
Online availability of Sanofi's half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.